Addressing Disparities and Optimizing Treatment Selection for African American Prostate Cancer Patients

Addressing Disparities and Optimizing Treatment Selection for African American Prostate Cancer Patients

Introduction:
Prostate cancer remains a significant health concern for men worldwide, and it is particularly prevalent among African American (AA) men. Studies have consistently shown that AA men experience higher rates of incidence and mortality from prostate cancer compared to their non-AA counterparts. Furthermore, a noticeable gap exists between AA and non-AA prostate cancer patients in terms of clinical trial enrollment rates. In this article, we will explore recent findings from two ASCO GU conferences and discuss the importance of addressing these disparities while optimizing treatment selection for AA prostate cancer patients.

ASCO GU 2021: Bridging the Gap in Clinical Trial Enrollment:
One of the key issues highlighted in a multi-institutional evaluation presented at ASCO GU 2021 was the disparity in clinical trial enrollment between AA and non-AA prostate cancer patients. It is crucial to understand that clinical trials play a vital role in advancing prostate cancer research and improving treatment outcomes. Yet, AA men are underrepresented in these trials, which can limit access to potentially life-saving treatments. By addressing this disparity, we can ensure that AA prostate cancer patients have equal opportunities to participate in clinical trials and receive the most effective treatments available.

ASCO GU 2020: Molecular Status and Treatment Selection:
Treatment selection in metastatic hormone-sensitive prostate cancer (mHSPC) is a complex decision-making process. Recent findings presented at ASCO GU 2020 shed light on the importance of considering molecular status when choosing between chemotherapy and androgen receptor (AR) targeted therapies. The study found that patients with the Basal subtype did not benefit from the addition of docetaxel to androgen deprivation therapy (ADT), whereas those with the Luminal B subtype experienced improved overall survival (OS) with the addition of docetaxel. This highlights the need for personalized treatment approaches based on the molecular characteristics of the tumor.

Addressing Disparities and Optimizing Treatment Selection:
To address the disparities faced by AA prostate cancer patients and optimize treatment selection, healthcare providers and researchers can take several actionable steps:

1. Enhance Diversity in Clinical Trials: To improve the representation of AA men in clinical trials, efforts should be made to enhance diversity among trial participants. This could involve targeted outreach programs, community engagement, and education initiatives that raise awareness about the importance of clinical trial participation.

2. Implement Molecular Testing: Incorporating molecular testing into routine clinical practice can help guide treatment decisions and improve outcomes for AA prostate cancer patients. Identifying the molecular subtype of a patient's tumor can assist in selecting the most appropriate treatment, whether it be chemotherapy or AR targeted therapies.

3. Promote Cultural Competence: Healthcare providers should strive to cultivate cultural competence when treating AA prostate cancer patients. This involves understanding and respecting the unique cultural, social, and historical factors that may contribute to health disparities. By fostering culturally sensitive care, healthcare providers can build trust and improve patient outcomes.

Conclusion:
Addressing the disparities faced by AA prostate cancer patients and optimizing treatment selection is crucial for improving outcomes in this population. By enhancing diversity in clinical trials, implementing molecular testing, and promoting cultural competence, we can bridge the gap in clinical trial enrollment and ensure that AA prostate cancer patients receive personalized, effective treatments. Through these proactive measures, we can work towards reducing the incidence and mortality rates of prostate cancer among African American men.